The District of Delaware granted Gordon Silver Limited and Verity Pharmaceuticals Inc.'s partial motion to dismiss Antares Pharma Inc.'s claims for trademark infringement and contributory trademark infringement alleging the improper sale of oral testosterone products for testosterone replacement therapy in adult males. The court determined that the first sale doctrine precludes the claims as a matter of law.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.